<DOC>
	<DOCNO>NCT01011283</DOCNO>
	<brief_summary>The purpose study compare response patient Intermediate High Risk myelodysplastic syndrome ( MDS ) follow treatment decitabine azacitidine .</brief_summary>
	<brief_title>To Demonstrate Superiority Decitabine Over Azacitidine Subjects With Intermediate- High-risk MDS .</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion Criteria Subjects meet follow criterion may include study : 1 . Must diagnosis primary myelodysplastic syndrome ( MDS ) Intermediate1 transfusion dependent , Intermediate2 , Highrisk [ define International Prognostic Scoring System ( IPSS ) score â‰¥0.5 ] recognize FrenchAmericanBritish ( FAB ) classification 2 . Male female , 18 year age older sign informed consent 3 . Adequate renal function 4 . Demonstrated normal liver function 5 . Female subject childbearing age must negative pregnancy test within 1 week study entry agree use adequate contraception duration trial minimum six month last dose decitabine azacitidine receive . 6 . Male subject must agree use adequate contraception duration trial minimum six month last dose decitabine azacitidine receive . Exclusion Criteria Subjects meet follow criterion exclude participation study : 1 . Current use radiotherapy extramedullary disease 2 week prior enter study ( permit &gt; 2 week study entry recover toxic effect therapy ) 2 . Systemic fungal , bacterial , viral infection control ( i.e. , ongoing sign symptom infection without improvement despite appropriate treatment ) 3 . Pregnancy current lactation 4 . Significant concurrent disease , illness , psychiatric disorder 5 . Treatment investigational agent 30 day prior first dose decitabine azacitidine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>MDS</keyword>
	<keyword>Myelodysplastic Syndromes</keyword>
</DOC>